In this episode of Life Lived Better, Joseph and Paula explore one of the most promising and controversial developments in addiction and mental health treatment: psychedelic-assisted therapy. They examine the history and emerging science behind psilocybin, MDMA, ibogaine, and ayahuasca, discussing what researchers are learning about their potential to address addiction, trauma, depression, and other behavioral health concerns. Special attention is given to ibogaine, including its unusual history in addiction treatment, potential effects on withdrawal and cravings, and the serious medical risks that make careful screening and supervision essential.

Rather than presenting psychedelics as miracle treatments or dismissing them because of their controversial history the episode focuses on what the evidence actually tells us. Our co-hosts explain the important differences between carefully controlled clinical research and underground treatment settings, who may not be appropriate candidates for these therapies, and why preparation, medical oversight, therapy, and follow-up matter. Ultimately, they consider whether psychedelic-assisted therapies could someday become another evidence-based pathway to recovery while emphasizing a central message: good clinical practice requires curiosity, caution, and a willingness to follow the evidence wherever it leads.

Questions? If you have questions, you would like Joseph and Paula to address during an upcoming episode of Questions for Counselors, feel free to reach out through the website at www.lifelivedbetter.net or email them directly at Info@lifelivedbetter.net

Just a reminder - Anything shared during this and all other episodes is based on personal experiences and opinions. It is not to be viewed as professional counseling or advice - it is solely our opinion. Information shared does not represent our employers or profession.

We would love for you to rate our show and tell others about us.

And remember, Knowledge leads to a Life Lived Better.

Resources used to create this episode:

Johns Hopkins Center for Psychedelic and Consciousness Research

Psychedelic and Dissociative Drugs | National Institute on Drug Abuse (NIDA)

Psychedelic Drugs: Considerations for Clinical Investigations | FDA